Although no FDA-licensed antagonists of VEGF are available for use in prematurity, intravitreal bevacizumab showed promising results for zone I or zone II posterior stage 3 + ROP, with a portion of non-responsive patients and numerous unwanted side effects (Yang et al., 2016). The gene discussed is VEGFA; the disease is retinopathy of prematurity.